Atlas Trials

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Clinical trial NCT02142049 · COMPLETED

Trial details

NCT number
NCT02142049
Sponsor
Pharmacyclics LLC.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Diffuse Large B Cell Lymphoma RelapsedDiffuse Large B Cell Lymphoma Refractory
Start date
2014-05-01
Primary completion
2017-08-01
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.